What's Going On With Mustang Bio Stock Tuesday?
Portfolio Pulse from Dylan Berman
Mustang Bio, Inc. (NASDAQ:MBIO) shares are trending upward after the company announced positive safety and efficacy data from its Phase 1/2 clinical trial of MB-106, a potential treatment for certain blood cancers. The data showed a 90% response rate with three complete responses, one of which remains in complete remission at 31 months. The data was presented at the European Hematology Association 2024 Hybrid Congress.
June 18, 2024 | 3:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mustang Bio shares are up 35.9% following the release of positive Phase 1/2 trial data for MB-106, a potential treatment for blood cancers. The trial showed a 90% response rate with three complete responses, one of which remains in complete remission at 31 months.
The positive trial data significantly boosts investor confidence in Mustang Bio's MB-106 treatment, leading to a substantial increase in the stock price. The high response rate and long-term remission are particularly encouraging for future revenue potential.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100